Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Mar 7;57(6):1105–1114. doi: 10.1093/rheumatology/kex525

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Published by Oxford University Press on behalf of the British Society for Rheumatology 2018. This work is written by US Government employees and is in the public domain in the US.

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/about_us/legal/notices)

PMC Copyright notice

Fig. 1 — BMD is significantly increased in the lumbar spine following MR1 treatment

Mice (female C57BL6) were administered Ig (control) or MR1 for 6 months, beginning at 5 months of age. BMD was quantified by DEXA at baseline and at 11 months of age and data are presented as BMD (g/cm²), as well as BMD (% change from baseline) for total body BMD (A and B), lumbar spine (C and D), femur (E and F) and tibia (G and H). Mean (s.d.). *P < 0.05; **P < 0.01; by Student’s t-test. n = 8 Ig and 8 MR1 mice/group. DEXA: dual energy x-ray absorptiometry; BMD: bone mineral density.